

Supplementary Material

Synthesis and exploratory biological evaluation of 3-[(N-4-benzyloxyphenyl)iminoethyl]- and 3-(1-hydrazonoethyl)-4-hydroxycoumarins

Meloddy H. Manyeruke^a, Heinrich C. Hoppe^{b,c}, Michelle Isaacs^c, Ronnett Seldon,^d Digby F. Warner,^e
Rui W.M. Krause,^{a,c*} and Perry T. Kaye^{a,c*}

^aDepartment of Chemistry, ^b Department of Biochemistry and Microbiology and ^cCentre for Chemico- and Biomedical Research (CCBR), Rhodes University, Makhanda/Grahamstown, 6140, South Africa.

^dDrug Discovery and Development Centre (H3-D), Department of Chemistry, University of Cape Town, Rondebosch 7701, South Africa

^eMolecular Mycobacteriology Research Unit, Department of Pathology and Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa

Email: P.Kaye@ru.ac.za; R.Krause@ru.ac.za

Table of Contents

Biological studies	S2
NMR spectra	S5
HRMS Spectrometric data.....	S25

Biological studies






To assess antimalarial activity, percentage viability of *Plasmodium falciparum* (3D7 strain) parasites incubated for 48 hours with 20 μM of the test compounds was determined by detecting plasmodium lactate dehydrogenase (pLDH) activity as described previously by Lunga *et al.* (*ChemMedChem* **2018**, *13*, 1352-1362). For anti-trypanosomal and cytotoxicity evaluation, percentage viability of *Trypanosoma brucei brucei* (427 strain) parasites or HeLa cells incubated with 20 μM of the test compounds for 48 hours was determined using resazurin, as previously described by Veale and Hoppe (*Med. Chem. Commun.* **2018**, *9*, 2037).

Table 1. Bioassay data for compounds **9a-f** showing % viability of pLDH, *T.b. brucei* and HeLa cells at 20 μM concentrations


Compound	R	PLDH % parasite viability	<i>T.b. brucei</i> % parasite viability	Cytotoxicity % HeLa cells viability
9a	H	93.0	33.5	82.6
9b	F	100.0	37.9	77.7
9c	Cl	94.2	31.3	96.3
9d	Br	100.0	23.3	100.0
9e	Me	100.0	96.4	100.0
9f	MeO	71.1	89.1	100.0
Control		IC ₅₀ = 0.010 μM ^a	IC ₅₀ = 0.022 μM ^b	IC ₅₀ = 0.019 μM ^c

Controls: ^a chloroquine; ^b pentamidine and ^c emetine

Table 2. Bioassay data for compounds **13a-g**, showing % viability of pLDH, *T.b. brucei* and HeLa and activity against mycobacterial cells at 20 μ M concentrations.

	Ar	PLDH % viability ^a	<i>T.b. brucei</i> % viability ^b	% HeLa cells viability ^c	Visual	Calculated
					MIC ₉₀ 7D 7H9 GLU CAS Tx(μ M)	MIC ₉₀ 7D 7H9 GLU CAS Tx (μ M)
13a		100.00	97.40	96.98	>125	>125
13b		100.00	52.34	92.26	>125	>125
13c		100.00	80.86	89.75	125	>125
13d		100.00	100.00	83.50	-	-
13e		63.93	100.22	67.78	>125	>125
13f		81.62	58.11	59.80	>125	>125
13g		86.51	1.53 (IC₅₀ 0.90)	65.25	62.50	62.44
Control		IC ₅₀ = 0.01 μ M ^a	IC ₅₀ = 0.022 μ M ^b	IC ₅₀ = 0.021 μ M ^c	0.019 ^d	0.007 ^d

Controls. ^a Chloroquine ^b Pentamidine ^c emetine ^d Rifampicin ^e IC₅₀ value

Table 3. Bioassay data for compounds **15a-g**, showing % activity against pLDH, *T.b. brucei* and HeLa cells at 20 μ M concentrations

Compound	Ar	PLDH % viability ^a	<i>T.b. brucei</i> % viability ^b	Cytotoxicity % HeLa cells viability
15a		100.00	96.35	78.49
15b		100.00	100.00	78.04
15c		100.00	94.57	84.71
15d		100.00	90.96	80.70
15e		100.00	64.77	72.24
15f		100.00	90.01	89.55
15g		100.00	80.49	79.38
Control		IC ₅₀ = 0.01 μ M ^a	IC ₅₀ = 0.022 μ M	IC ₅₀ = 0.021 μ M ^c

Controls. ^a chloroquine ^b pentamidine ^c emetine




Figure 3. 400 MHz ^1H NMR spectrum of compound **9b** in CDCl_3 .




Figure 4. 100 MHz ^{13}C NMR spectrum of compound **9b** in CDCl_3 .




Figure 5. 400 MHz ^1H NMR spectrum of compound **9c** in CDCl_3 .




Figure 6. 100 MHz ^{13}C NMR spectrum of compound **9c** in CDCl_3 .




Figure 7. 400 MHz ^1H NMR spectrum of compound **9d** in CDCl_3 .




Figure 8. 100 MHz ^{13}C NMR spectrum of compound **9d** in CDCl_3 .




Figure 9. 400 MHz ^1H NMR spectrum of compound **9e** in CDCl_3 .




Figure 10. 100 MHz ^{13}C NMR spectrum of compound **9e** in CDCl_3 .




Figure 11. ^1H 400 MHz NMR spectrum of compound **9f** in CDCl_3 .






Figure 12. 100 MHz ^{13}C NMR spectrum of compound **9f** in CDCl_3 .

3-[1-(Benzylidenehydrazono)ethyl]-4-hydroxycoumarins **13a-g**Figure 13. ¹H 600 MHz NMR spectrum of compound **13a** in CDCl₃.Figure 14. 150 MHz ¹³C NMR spectrum of compound **13a** in CDCl₃.




Figure 15. ^1H 600 MHz NMR spectrum of compound **13b** in CDCl_3 .




Figure 16. 150 MHz ^{13}C NMR spectrum of compound **13b** in CDCl_3 .




Figure 17. ¹H 600 MHz NMR spectrum of compound **13c** in CDCl₃.




Figure 18. 150 MHz ¹³C NMR spectrum of compound **13c** in CDCl₃.




Figure 19. ¹H 600 MHz NMR spectrum of compound **13d** in CDCl₃.




Figure 20. 150 MHz ¹³C NMR spectrum of compound **13d** in CDCl₃.




Figure 21. ¹H 600 MHz NMR spectrum of compound **13e** in DMSO-*d*₆.




Figure 22. 150 MHz ¹³C NMR spectrum of compound **13e** in DMSO-*d*₆.





Figure 23. ¹H 400 MHz NMR spectrum of compound **13f** in DMSO-*d*₆.






Figure 25. ¹H 400 MHz NMR spectrum of compound **13g** in DMSO-*d*₆.




Figure 26. 100 MHz ¹³C NMR spectrum of compound **13g** in DMSO-*d*₆.


3-{1-[(prop-2-yn-1-yloxy)benzylidenehydrazono]ethyl}-4-hydroxycoumarins 15a-g

Figure 27. ¹H 400 MHz NMR spectrum of compound **15a** in CDCl₃.




Figure 28. 100 MHz ¹³C NMR spectrum of compound **15a** in CDCl₃.




Figure 29. ¹H 300 MHz NMR spectrum of compound **15b** in CDCl₃.




Figure 30. 75 MHz ¹³C NMR spectrum of compound **15b** in CDCl₃.




Figure 31. ¹H 300 MHz NMR spectrum of compound **15c** in CDCl₃.




Figure 32. 75 MHz ¹³C NMR spectrum of compound **15c** in CDCl₃.




Figure 33. ^1H 600 MHz NMR spectrum of compound **15d** in CDCl_3 .




Figure 34. 150 MHz ^{13}C NMR spectrum of compound **15d** in CDCl_3 .




Figure 35. ¹H 400 MHz NMR spectrum of compound **15e** in CDCl₃.




Figure 36. 100 MHz ¹³C NMR spectrum of compound **15e** in CDCl₃.




Figure 37. ¹H 600 MHz NMR spectrum of compound **15f** in CDCl₃.




Figure 38. 150 MHz ¹³C NMR spectrum of compound **15f** in CDCl₃.




Figure 39. ¹H 400 MHz NMR spectrum of compound **15g** in CDCl₃.






Figure 40. 100 MHz ¹³C NMR spectrum of compound **15g** in CDCl₃.

HRMS Spectrometric data


9a




9b




9c




9d





9e




9f




13a**13b**


13c




13d



13e




13f




13g

MMG3


MS_Direct_211013_RU_52 37 (0.232) Cm (17.47-2.7)

1: TOF MS ES+
2.68e5



15a



15b



15c




15d


Elemental Composition

File Edit View Process Help


</



15e



15f



15g

